Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative predictive value was lower at approximately 70%.
Background Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer treatment, but their effectiveness is limited. Fecal microbiota transplantation (FMT), which alters the gut microbiome, has shown promise in enhancing ICIs’ therapeutic effects. Methods We conducted a ...
Renal cell carcinoma (RCC), particularly the clear-cell subtype (ccRCC), accounts for 75-85% of kidney cancers and exhibits distinct genetic and ...
Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.
Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.
Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.
Panelists discuss how PET imaging for kidney cancer includes prostate-specific membrane antigen, which is sometimes expressed in renal cell carcinoma, though its utility remains unclear, whereas fluorodeoxyglucose PET can be useful for metabolic activity assessment despite limitations with ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.